Report Adverse Event or Product Quality Complaint   US Site   Global Site             

Header Logo
  • Prescribing Information
  • Therapy areas
    • All Therapeutic Areas
    • Cardiovascular, Renal and Metabolism
    • Immunology
    • Infection
    • Oncology
    • Rare Disease (Alexion)
    • Respiratory
  • Disease Education
  • Resources
    • Congress Library
    • Clinical Trials
    • Continuing Education
    • Patient Support
    • Pipeline
  • Connect
    • Connect with an MSL
    • Connect with an MSL
    • Submit an Medical Information Request
    • Give Feedback

Search Medical Information

Login

Request a field medical follow-up

  • Home
  • Congress Library
  • ESC-HFA 2026

European Society of Cardiology-Heart Failure: Heart Failure Association

May 09 - 12, 2026

  1. All
  2. ATTR Amyloidosis
  3. Heart Failure
  4. Heart Failure & Chronic Kidney Disease
  5. Farxiga (dapagliflozin)
  6. Hypertension

PDF

Age- and sex-associated cardiac features and diagnostic latency in patients with ATTR-mixed and PN phenotypes assessed in a prospective multi-national real-world study

PDF

A pan-european multi-level pathway mapping framework for heart failure and cardiovascular care

VIDEO

Design and baseline characteristics of the CARDIO-TTRansform phase 3 randomized controlled trial of eplontersen for patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM)

PDF

Mapping variations in heart failure care and guideline adherence across Europe

PDF

Outpatient clinic visits before and after hospitalizations for heart failure with and without transthyretin amyloid cardiomyopathy

PDF

Impact of the implementation of standardised early identification and diagnosis of transthyretin amyloidosis in high-risk patients: protocol of a high-quality diagnostic study (HI-QUAL ATTR)

PDF

Effects of AZD3427 in participants with heart failure and pulmonary hypertension group 2: a phase IIb randomised, double-blind, placebo-controlled study

HTML

Development of case definition criteria for querying insurance databases in heart failure epidemiological investigations: Rationale and design of the HF-EPI-HUN study

HTML

Trends in standardized mortality in men and women with heart failure - a nationwide analysis of 700,000 individuals over two decades

HTML

Anthropometric adiposity measures and natriuretic peptides in heart failure screening: population-based evidence from the PORTHOS study

HTML

Initiation of mineralocorticoid receptor antagonists in cardiorenal patients: potassium changes, hyperkalaemia risk and discontinuation in the CaRe study

HTML

Care discrepancy in the management of the cardiorenal-metabolic syndrome: Real-world analysis of SGLT2 inhibitor use in heart failure, chronic kidney disease, and type 2 diabetes

HTML

Multimorbidity in heart failure: real-world burden, treatment gaps, and resource utilization in Germany

HTML

Bridging the blood pressure gap in Germany: Real world patterns of control, resistance, and the heart failure interface

VIDEO

Design and baseline characteristics of the CARDIO-TTRansform phase 3 randomized controlled trial of eplontersen for patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM)

PDF

Age- and sex-associated cardiac features and diagnostic latency in patients with ATTR-mixed and PN phenotypes assessed in a prospective multi-national real-world study

PDF

A pan-european multi-level pathway mapping framework for heart failure and cardiovascular care

PDF

Mapping variations in heart failure care and guideline adherence across Europe

PDF

Outpatient clinic visits before and after hospitalizations for heart failure with and without transthyretin amyloid cardiomyopathy

PDF

Impact of the implementation of standardised early identification and diagnosis of transthyretin amyloidosis in high-risk patients: protocol of a high-quality diagnostic study (HI-QUAL ATTR)

PDF

Effects of AZD3427 in participants with heart failure and pulmonary hypertension group 2: a phase IIb randomised, double-blind, placebo-controlled study

HTML

Development of case definition criteria for querying insurance databases in heart failure epidemiological investigations: Rationale and design of the HF-EPI-HUN study

HTML

Trends in standardized mortality in men and women with heart failure - a nationwide analysis of 700,000 individuals over two decades

HTML

Anthropometric adiposity measures and natriuretic peptides in heart failure screening: population-based evidence from the PORTHOS study

HTML

Initiation of mineralocorticoid receptor antagonists in cardiorenal patients: potassium changes, hyperkalaemia risk and discontinuation in the CaRe study

HTML

Care discrepancy in the management of the cardiorenal-metabolic syndrome: Real-world analysis of SGLT2 inhibitor use in heart failure, chronic kidney disease, and type 2 diabetes

HTML

Multimorbidity in heart failure: real-world burden, treatment gaps, and resource utilization in Germany

HTML

Bridging the blood pressure gap in Germany: Real world patterns of control, resistance, and the heart failure interface

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Connessiallasalute.it

This site is intended for healthcare professionals practicing in the US.
©2026 AstraZeneca. All rights reserved.

US-107328
Last Updated 5/26

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities  

Survey Feedback

Your Privacy Choice

Consumer Health Data
Privacy Notice

Privacy Notice | Legal Notice | Cookie Preferences

Welcome to AstraZeneca Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

 

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

 

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?
This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am not a healthcare professional practicing in the United States